FR21C1049I2 - PHARMACEUTICAL COMPOSITION COMPRISING CITRATE AND BICARBONATE SALTS, AND ITS USE FOR THE TREATMENT OF CYSTINURIA - Google Patents

PHARMACEUTICAL COMPOSITION COMPRISING CITRATE AND BICARBONATE SALTS, AND ITS USE FOR THE TREATMENT OF CYSTINURIA

Info

Publication number
FR21C1049I2
FR21C1049I2 FR21C1049C FR21C1049C FR21C1049I2 FR 21C1049 I2 FR21C1049 I2 FR 21C1049I2 FR 21C1049 C FR21C1049 C FR 21C1049C FR 21C1049 C FR21C1049 C FR 21C1049C FR 21C1049 I2 FR21C1049 I2 FR 21C1049I2
Authority
FR
France
Prior art keywords
cystinuria
citrate
treatment
pharmaceutical composition
bicarbonate salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR21C1049C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advicenne SA
Original Assignee
Advicenne SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44146941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR21C1049(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Advicenne SA filed Critical Advicenne SA
Publication of FR21C1049I1 publication Critical patent/FR21C1049I1/fr
Application granted granted Critical
Publication of FR21C1049I2 publication Critical patent/FR21C1049I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/745—Polymers of hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
FR21C1049C 2010-11-18 2021-10-27 PHARMACEUTICAL COMPOSITION COMPRISING CITRATE AND BICARBONATE SALTS, AND ITS USE FOR THE TREATMENT OF CYSTINURIA Active FR21C1049I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1059474A FR2967578B1 (en) 2010-11-18 2010-11-18 PHARMACEUTICAL COMPOSITION COMPRISING CITRATE AND BICARBONATE SALTS AND USE THEREOF FOR THE TREATMENT OF CYSTINURIA
PCT/FR2011/052697 WO2012066257A1 (en) 2010-11-18 2011-11-18 Pharmaceutical composition comprising citrate and bicarbonate salts, and use thereof for treating cystinuria

Publications (2)

Publication Number Publication Date
FR21C1049I1 FR21C1049I1 (en) 2021-12-10
FR21C1049I2 true FR21C1049I2 (en) 2022-09-30

Family

ID=44146941

Family Applications (2)

Application Number Title Priority Date Filing Date
FR1059474A Active FR2967578B1 (en) 2010-11-18 2010-11-18 PHARMACEUTICAL COMPOSITION COMPRISING CITRATE AND BICARBONATE SALTS AND USE THEREOF FOR THE TREATMENT OF CYSTINURIA
FR21C1049C Active FR21C1049I2 (en) 2010-11-18 2021-10-27 PHARMACEUTICAL COMPOSITION COMPRISING CITRATE AND BICARBONATE SALTS, AND ITS USE FOR THE TREATMENT OF CYSTINURIA

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR1059474A Active FR2967578B1 (en) 2010-11-18 2010-11-18 PHARMACEUTICAL COMPOSITION COMPRISING CITRATE AND BICARBONATE SALTS AND USE THEREOF FOR THE TREATMENT OF CYSTINURIA

Country Status (16)

Country Link
US (1) US9636304B2 (en)
EP (1) EP2640363B1 (en)
JP (1) JP5879359B2 (en)
KR (1) KR101699581B1 (en)
AU (1) AU2011331019B2 (en)
CA (1) CA2816660C (en)
DK (1) DK2640363T3 (en)
ES (1) ES2553424T3 (en)
FR (2) FR2967578B1 (en)
HU (1) HUE026230T2 (en)
IL (1) IL226373A (en)
MX (1) MX338975B (en)
NZ (1) NZ611026A (en)
PL (1) PL2640363T3 (en)
WO (1) WO2012066257A1 (en)
ZA (1) ZA201303695B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11273140B2 (en) * 2013-06-06 2022-03-15 Stefanie A. Seixas-Mikelus Juice beverage for prevention and treatment of renal stones
FR3009496B1 (en) * 2013-08-12 2016-02-05 Mohamed Skiba MULTIPARTICULAR FORMS WITH PROLONGED RELEASE, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING SAME FOR THE TREATMENT AND / OR PREVENTION OF CYCTINURIA
CA3067567A1 (en) * 2017-06-16 2018-12-20 Altibio, Inc. Modified-release tiopronin compositions, kits and methods for treating cystinuria and related disorders
US20230082078A1 (en) * 2021-08-24 2023-03-16 Laminaria Group Ab Sodium bicarbonate nutritional supplement

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903255A (en) * 1971-05-17 1975-09-02 Rohm & Haas Effervescent potassium chloride tablet
HU165181B (en) 1971-11-08 1974-07-27
US4451454A (en) * 1981-06-16 1984-05-29 Wong Dennis W Prophylaxis and treatment of thromboembolic disorders in man and in warm-blooded animals with bicarbonate salts of alkali metals
GB2130087A (en) * 1982-09-22 1984-05-31 Dr Joachime Helbig Pharmaceutical oral dosage forms of an active agent capable of forming or releasing bicarbonate ions
JPS60197624A (en) * 1984-03-21 1985-10-07 Nippon Chemiphar Co Ltd Urine-alkalizing food composition
CA1326040C (en) 1989-11-16 1994-01-11 Neill B. Walsdorf Magnesium-potassium citrate
JP2941163B2 (en) * 1993-02-19 1999-08-25 武田薬品工業株式会社 Pet urinary stone disease treatment / prevention agent and treatment method
US5674529A (en) * 1995-06-06 1997-10-07 Church & Dwight Co., Inc. Alkalinizing potassium salt controlled release preparations
US5888544A (en) * 1996-06-20 1999-03-30 Gerhard Gergely Effervescent system for effervescent tablets and effervescent granules
EP1970066A1 (en) * 2007-03-12 2008-09-17 Medice Arzneimittel Pütter GmbH & Co. KG Pharmaceutical compound for treating acidaemia

Also Published As

Publication number Publication date
KR101699581B1 (en) 2017-01-24
JP5879359B2 (en) 2016-03-08
FR2967578B1 (en) 2012-12-28
CA2816660C (en) 2017-07-04
PL2640363T3 (en) 2016-01-29
US20130236545A1 (en) 2013-09-12
ZA201303695B (en) 2014-07-30
CA2816660A1 (en) 2012-05-24
AU2011331019A1 (en) 2013-06-13
ES2553424T3 (en) 2015-12-09
EP2640363B1 (en) 2015-08-26
JP2013542975A (en) 2013-11-28
AU2011331019B2 (en) 2016-04-07
MX338975B (en) 2016-05-06
FR2967578A1 (en) 2012-05-25
US9636304B2 (en) 2017-05-02
DK2640363T3 (en) 2015-12-14
FR21C1049I1 (en) 2021-12-10
NZ611026A (en) 2014-12-24
IL226373A0 (en) 2013-07-31
WO2012066257A1 (en) 2012-05-24
MX2013005482A (en) 2013-08-29
IL226373A (en) 2016-04-21
EP2640363A1 (en) 2013-09-25
KR20130119450A (en) 2013-10-31
HUE026230T2 (en) 2016-06-28

Similar Documents

Publication Publication Date Title
FR21C1049I2 (en) PHARMACEUTICAL COMPOSITION COMPRISING CITRATE AND BICARBONATE SALTS, AND ITS USE FOR THE TREATMENT OF CYSTINURIA
FR20C1020I1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DROSPIRENONE AND CONTRACEPTIVE KIT
EA201491009A1 (en) PLATINOUS LIZATE GEL
FR2948016B1 (en) ORTHESIS FOR THE TREATMENT OF RHIZARTHROSIS
BR112012022878A2 (en) compound, pharmaceutical composition, compound use and method of treatment
BR112013012854A2 (en) treatment methods using selective bcl-2 inhibitors
UA109650C2 (en) BIS-ARLYZED ARILTRIAZOLONS AND THEIR APPLICATIONS
BR112013013311A2 (en) cytotoxicity-inducing therapeutic agent
BR112014023937A2 (en) pharmaceutical composition, pharmaceutical combination and treatment method
BR112014019233A2 (en) medicinal plasters to create or maintain an area of human tissue free from contaminants
BRPI1012116A2 (en) pharmaceutical composition for the treatment of heart disease
BR112013013414A2 (en) blood collection devices containing blood stabilizing agent
PL2600865T3 (en) Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
FR2907011B1 (en) USE OF CITRULLINE FOR THE TREATMENT OF DENUTRITION CONDITIONS
EP2601951A4 (en) Pharmaceutical composition for treating hemorrhage caused by blood clotting disorder and use thereof
ZA201203281B (en) Pharmaceutical combinations, pharmaceutical compositions, medicament and method for the treatment of animals
HUE040152T2 (en) 2-piperazin-1-yl-4h-1,3-benzothiazin-4-one derivatives and their use for the treatment of mammalian infections
BR112013015798A2 (en) imaging agent composition, method of preparing an imaging agent composition, and pharmaceutical composition
BR112013013242A2 (en) extracorporeal blood treatment apparatus
DE102009018133A8 (en) Pharmaceutical composition for the treatment of dermatological autoimmune diseases
FR2986538B1 (en) USE OF MIR-199A-5P OF ITS TARGETS AND / OR INHIBITORS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF FIBROPROLIFERATIVE DISEASES
BRPI1013525A2 (en) pharmaceutical agent, pharmaceutical composition, and method of treating influenza
FR2977798B1 (en) USE OF OLIGOSACCHARIDE COMPOUNDS FOR THE PREVENTION AND TREATMENT OF PATHOLOGICAL SCARS
FR2997837B1 (en) OSTEOSYNTHESIS DEVICE FOR THE TREATMENT OF FRACTURES OF FEMUR.
FR2901703B1 (en) USE OF ZATOSETRON FOR THE TREATMENT OF ROSACEA, AND PHARMACEUTICAL COMPOSITIONS